Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

$18.21 +0.71 (+4.06%)

Closing price 10/8/2026 04:00 PM Eastern

Extended Trading

$17.98 -0.23 (-1.26%)

As of 10/8/2026 07:42 PM Eastern

Compare

Sarepta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Reduce

Based on 21 Analyst Ratings

Sell
8

Hold
6

Buy
7

Based on 21 Wall Street analysts who have issued ratings for Sarepta Therapeutics in the last 12 months, the stock has a consensus rating of "Reduce." Out of the 21 analysts, 8 have given a sell rating, 6 have given a hold rating, and 7 have given a buy rating for SRPT.

Consensus Price Target

$22.59
24.04% Upside

According to the 21 analysts' twelve-month price targets for Sarepta Therapeutics, the average price target is $22.59. The highest price target for SRPT is $38.00, while the lowest price target for SRPT is $5.00. The average price target represents a forecasted upside of 24.04% from the current price of $18.21.

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Get the Latest News and Ratings for SRPT and Related Stocks

Enter your email address to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors.

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

SRPT Analyst Ratings Over Time

Type	Current Forecast 10/9/25 to 10/9/26	1 Month Ago 9/9/25 to 9/9/26	3 Months Ago 7/11/25 to 7/11/26	1 Year Ago 10/9/24 to 10/9/25
Strong Buy	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)	0 Strong Buy rating(s)
Buy	7 Buy rating(s)	9 Buy rating(s)	9 Buy rating(s)	8 Buy rating(s)
Hold	6 Hold rating(s)	6 Hold rating(s)	10 Hold rating(s)	13 Hold rating(s)
Sell	8 Sell rating(s)	5 Sell rating(s)	7 Sell rating(s)	7 Sell rating(s)
Consensus Price Target	$22.59	$25.06	$25.09	$39.04
Forecasted Upside	24.04% Upside	13.80% Upside	32.41% Upside	68.79% Upside
Consensus Rating	Reduce	Hold	Hold	Hold

SRPT Analyst Recommendations By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.

SRPT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.

Sarepta Therapeutics Stock vs. The Competition

Type	Sarepta Therapeutics	Healthcare Companies	Broader Market
Consensus Rating Score	1.95	2.32	2.52
Consensus Rating	Reduce	Hold	Moderate Buy
Predicted Upside	24.04% Upside	903.14% Upside	19.63% Upside
News Sentiment Rating	Neutral News See Recent SRPT News	Neutral News	Neutral News

Recent Analyst Forecasts and Stock Ratings

Show

Rating

Upside/Downside

Action

Report Date

0 Results

Export

Date	Brokerage	Analyst	Action	Rating	Price Target	Report Date Upside/Downside
10/8/2026	Royal Bank Of Canada 3 of 5 stars	Brian Abrahams 5 of 5 stars	Lower Target	Sector Perform	$19.00 ➝ $17.00	-2.30%
10/5/2026	Zacks Research 4 of 5 stars		Downgrade	Hold ➝ Strong Sell
10/5/2026	HC Wainwright 4 of 5 stars	Mitchell S. Kapoor 3 of 5 stars	Reiterated Rating	Sell	$5.00	-71.43%
9/30/2026	JPMorgan Chase & Co. Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Anupam Rama Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$23.00 ➝ $20.00	+9.10%
9/28/2026	Needham & Company LLC Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gil Blum Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Underperform
9/24/2026	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Downgrade	Sell (D-) ➝ Sell (E+)
9/23/2026	William Blair Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Upgrade	Hold
9/9/2026	Benchmark Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Reiterated Rating	Sell
7/9/2026	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Biren Amin Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$23.00 ➝ $20.00	-1.57%
7/9/2026	Wolfe Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andy Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Peer Perform ➝ Outperform	$27.00	+33.60%
Get the Latest News and Ratings for SRPT and Related Stocks Enter your email address below to receive the latest news and analysts' ratings for Sarepta Therapeutics and its competitors with MarketBeat's FREE daily newsletter.
3/26/2026	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Outperform	$29.00 ➝ $35.00	+56.71%
3/26/2026	Deutsche Bank Aktiengesellschaft Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating		Boost Target	Sell	$12.00 ➝ $14.00	-37.32%
3/26/2026	Citigroup Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yigal Nochomovitz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Sell	$9.00 ➝ $13.00	-40.49%
3/19/2026	Oppenheimer Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$37.00	+117.12%
3/12/2026	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Uy Ear Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Outperform	$26.00 ➝ $31.00	+81.92%
3/3/2026	Loop Capital Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ilya Zubkov Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Set Target		$25.00	+57.53%
3/3/2026	Jefferies Financial Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Andrew Tsai Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy	$30.00	+85.87%
2/27/2026	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Yanan Zhu Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Overweight	$45.00 ➝ $38.00	+128.13%
1/28/2026	Barclays Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gena Wang Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Equal Weight	$20.00	-9.79%
11/5/2025	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Debjit Chattopadhyay Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Buy	$22.00 ➝ $19.00	+3.54%
11/4/2025	Robert W. Baird Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Brian Skorney Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Lower Target	Neutral	$21.00 ➝ $15.00	-38.65%
10/22/2025	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Tazeen Ahmad Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Underperform	$16.00 ➝ $18.00	-16.91%
9/22/2025	BMO Capital Markets Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kostas Biliouris Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Market Perform ➝ Outperform	$50.00	+186.86%
9/9/2025	Leerink Partners Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Joseph Schwartz Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Market Perform	$12.00 ➝ $15.00	-15.33%
8/7/2025	The Goldman Sachs Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Salveen Richter Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Neutral	$19.00	+9.05%
7/29/2025	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Matthew Harrison Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Boost Target	Equal Weight	$15.00 ➝ $20.00	+44.30%
7/29/2025	Sanford C. Bernstein Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	William Pickering Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Initiated Coverage	Market Perform	$13.00	-6.20%
7/21/2025	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Eliana Merle Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Buy ➝ Neutral
6/18/2025	TD Cowen Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Ritu Baral Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Buy ➝ Hold	$24.00	+11.32%
6/16/2025	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Kristen Kluska Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Overweight ➝ Neutral
6/6/2025	Scotiabank Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Louis Chen Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Upgrade	Sector Perform ➝ Sector Outperform	$80.00	+104.03%
5/8/2025	Evercore Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Gavin Clark-Gartner Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Downgrade	Outperform ➝ Inline	$50.00	+36.17%
10/10/2024	Raymond James Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Danielle Brill Subscribe to MarketBeat All Access for the analyst's recommendation accuracy rating	Reiterated Rating	Outperform	$150.00	+27.61%

Analyst ratings data on MarketBeat is provided by Benzinga and other data providers. This page was last refreshed on Friday at 01:00 AM ET.

SRPT Forecast - Frequently Asked Questions

According to the research reports of 21 Wall Street equities research analysts, the average twelve-month stock price forecast for Sarepta Therapeutics is $22.59, with a high forecast of $38.00 and a low forecast of $5.00.

21 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Sarepta Therapeutics in the last twelve months. There are currently 8 sell ratings, 6 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "reduce" SRPT shares.

According to analysts, Sarepta Therapeutics's stock has a predicted upside of 24.04% based on their 12-month stock forecasts.

Over the previous 90 days, Sarepta Therapeutics's stock had 4 upgrades and 4 downgrades by analysts.

Sarepta Therapeutics has been rated by research analysts at Benchmark, HC Wainwright, JPMorgan Chase & Co., Needham & Company LLC, Royal Bank Of Canada, Weiss Ratings, William Blair, and Zacks Research in the past 90 days.

Analysts like Sarepta Therapeutics less than other "healthcare" companies. The consensus rating for Sarepta Therapeutics is Reduce while the average consensus rating for "healthcare" companies is Hold. Learn more on how SRPT compares to other companies.

Stock Forecasts and Research Tools

Related Companies

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Sarepta Therapeutics Recommendations

MarketBeat monitors more than a dozen sources for Sarepta Therapeutics analyst ratings, with the most recent rating issued on 10/8/2026.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

SRPT Analyst Ratings Over Time

SRPT Analyst Recommendations By Month

SRPT Price Targets by Month

Sarepta Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

SRPT Forecast - Frequently Asked Questions

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Sarepta Therapeutics Recommendations

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Sarepta Therapeutics (SRPT) Stock Forecast & Price Target

Sarepta Therapeutics - Analysts' Recommendations and Stock Price Forecast (2026)

Consensus Rating

Consensus Price Target

SRPT Analyst Ratings Over Time

SRPT Analyst Recommendations By Month

SRPT Price Targets by Month

Sarepta Therapeutics Stock vs. The Competition

Recent Analyst Forecasts and Stock Ratings

SRPT Forecast - Frequently Asked Questions

What is Sarepta Therapeutics' forecast for 2026?

Should I buy or sell Sarepta Therapeutics stock right now?

Does Sarepta Therapeutics's stock price have much upside?

Has Sarepta Therapeutics been upgraded or downgraded by Wall Street analysts recently?

What analysts cover Sarepta Therapeutics?

Do Wall Street analysts like Sarepta Therapeutics more than its competitors?

Stock Forecasts and Research Tools

Today's Analyst Ratings

Top-Rated Stocks

More Ratings Tools

Brokerages With Sarepta Therapeutics Recommendations

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools